What is PT-141?
PT-141 — also known as Bremelanotide — is a synthetic peptide studied for its effects on sexual arousal. It's a cyclic heptapeptide and an active metabolite of Melanotan II, but where Melanotan II is studied mainly for pigmentation, PT-141 is studied for its activity on the melanocortin receptor system.
What makes it distinctive in the research literature is where it acts: PT-141 works through the central nervous system, not the vascular system.
How PT-141 Works — A Different Pathway
Most well-known compounds in this area (PDE5 inhibitors such as sildenafil) work on blood flow. PT-141 is studied for a completely different mechanism:
- It acts as an agonist at melanocortin receptors, principally MC3R and MC4R, which are found in the brain.
- Activity at these central receptors is associated in research with the regulation of sexual desire and arousal — a neurological pathway rather than a vascular one.
- Because the mechanism is central, it's studied in research models of arousal in both male and female subjects.
PT-141 is one of the few compounds in this space studied for a central (brain-mediated) mechanism rather than acting on blood vessels — which is why it attracts distinct research interest.
Key Research Areas
Sexual Arousal & Desire
PT-141's primary research focus is sexual arousal and desire, studied through its melanocortin activity in the central nervous system. This is the area it is most associated with in the literature, in both male and female research models.
Hypoactive Sexual Desire (HSDD)
Bremelanotide has been studied specifically in hypoactive sexual desire disorder in pre-menopausal women, which led to its most significant regulatory milestone (see Research Status below).
Route & Onset
In research, PT-141 is typically administered subcutaneously, and is studied as an "on-demand" compound used ahead of activity rather than taken continuously.
Research Status
PT-141 has a clearer regulatory record than most research peptides: as Bremelanotide (brand name Vyleesi), it was approved by the US FDA in 2019 for hypoactive sexual desire disorder in pre-menopausal women. That said, it is not approved by SAHPRA or registered for therapeutic use in South Africa, and LA LAB supplies it strictly as a research compound — for research use only, not for human consumption.
LA LAB PT-141
LA LAB supplies PT-141 (Bremelanotide) as a lyophilized 10 mg vial, third-party tested by Janoshik Analytical for purity and identity. View it on our PT-141 product page, and see our reconstitution & research guides for how it's prepared and measured.